Question explored with the scientific record
Do covid vaccines raise blood pressure?
The short version: the evidence shows a real, measurable blood pressure spike in a meaningful minority of recipients, but the studies are short-term and the long-term picture is not studied.
The meta-analysis of pharmacovigilance data found that about 3.2% of people reported abnormal blood pressure after COVID-19 vaccination, with 0.6% reaching stage III hypertension [3]. A study of 797 healthcare workers found 7 cases of grade 2 or 3 hypertension (0.9%), all resolving within 3-4 days [4]. A separate study of 287 workers found that 15 minutes after the first dose, 6.6% had a diastolic spike averaging 15 mmHg, and 5.2% had a systolic spike averaging 25 mmHg [1]. These are not trivial numbers for a single injection.
The mechanism is plausible. The spike protein and the inflammatory response it triggers can damage the glycocalyx and disrupt the zeta potential of red cells, causing blood sludging and microvascular resistance that forces the heart to pump harder. The renin-angiotensin system is directly involved: the spike protein binds ACE2, the enzyme that normally breaks down the vasoconstrictor angiotensin II, so blocking it raises blood pressure by design. One study even found that hypertensive patients had significantly higher anti-spike antibody levels after vaccination than normotensive patients, suggesting the immune system reacts differently in people with existing blood pressure problems [12].
| Blood pressure change | Frequency after dose 1 | Frequency after dose 2 |
|---|---|---|
| Systolic spike (mean +25-26 mmHg) | 5.2% [1] | 3.1% [1] |
| Diastolic spike (mean +15 mmHg) | 6.6% [1] | 9.1% [1] |
| Any abnormal BP (meta-analysis) | 3.2% [3] | - |
| Grade 2-3 hypertension (HCW study) | 0.9% [4] | - |
The evidence is all short-term, measured in minutes or days. No study in the retrieved evidence followed people for months or years to see if the spike becomes chronic or triggers sustained hypertension. The system has not run that study. The burden of proof is on the intervention, and the intervention has not met it for long-term blood pressure safety.
My call: the evidence shows a real, transient blood pressure increase in a few percent of recipients, but the long-term risk is unstudied. Confidence: moderate for the acute spike, low for the chronic question.
Sources examined 12
-
BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
This study investigates the effects of the BNT162b2 COVID-19 vaccine on blood pressure changes in healthcare workers before and 15 minutes after vaccination, revealing significant transient fluctuations in diastolic blood pressure and pulse pressure.
DOI: 10.3390/medicina58121789 -
Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination
This study presents a case of a patient diagnosed with anti-MOG associated disease (MOGAD) who developed intracranial hypertension following COVID-19 vaccination, highlighting the potential neurological complications associated with such vaccinations.
DOI: 10.1007/s00415-022-11130-x -
Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis
This systematic review and meta-analysis investigates the occurrence of abnormal blood pressure (BP) following COVID-19 vaccination, finding that approximately 3.20% of patients experience increased BP, with a notable incidence of stage III hypertension at 0.6%.
DOI: 10.3390/jcdd9050150 -
Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event
This study investigates the rare occurrence of significant blood pressure increases following the BNT162b2 mRNA COVID-19 vaccination among healthcare workers, finding that while such increases are infrequent, they tend to be transient and benign.
DOI: 10.3390/vaccines10050745 -
Comorbidities, Gender, and Race in the Severity of COVID-19
Diabetes and hypertension show limited independent impact on COVID-19 severity or mortality among hospitalized adults, but are associated with longer hospital stays and higher pre-admission vaccination; vaccination prior to admission modestly reduces severity, though observed mo…
DOI: 10.14738/bjhr.1206.19738 -
Central Retinal Vein Occlusion in a Young Woman with Diabetes and Hypertension after mRNA-Based COVID-19 Vaccination—A Case Report and Brief Review of the Literature
This case report describes a 25-year-old woman with diabetes and hypertension who developed central retinal vein occlusion (CRVO) after receiving the mRNA-based COVID-19 vaccine BNT162b2, highlighting the potential association between vaccination and ocular complications.
DOI: 10.3390/vaccines11020365 -
Vaccination Status and Symptom Severity in Covid-19 Patients
A cross-sectional study of 112 hospitalized COVID-19 patients in Yogyakarta, Indonesia found that incomplete vaccination status and hypertension are strongly associated with severe or critical symptoms, while complete vaccination markedly reduces this risk.
DOI: 10.31965/infokes.vol23.iss1.1351 -
Therapeutic vaccine for chronic diseases after the COVID-19 Era
A perspective on developing therapeutic vaccines for chronic diseases after the COVID-19 era, focusing on self-antigen (angiotensin II) epitope vaccines, their immunological mechanism involving T follicular helper cells, carrier/adjuvant strategies, preclinical and clinical evid…
DOI: 10.1038/s41440-021-00677-3 -
Pulmonary thromboembolism in mild and asymptomatic COVID-19 cases. A clinical conundrum in post-COVID era
Four adults with pulmonary embolism and pulmonary hypertension of unknown etiology, including cases with prior COVID-19 antibodies, suggest a possible link to undiagnosed or mild COVID-19 infection in the post-pandemic era and highlight the need to screen for post-COVID vascular…
DOI: 10.4081/cdr.10.10646 -
7053 Sex Differences in Endocrine-Related Pre-existing, COVID-19- and COVID-19 Vaccine-Related Health Conditions and Adverse Events
Global survey of approximately 8,000–10,000 participants reveals sex-based differences in endocrine-related pre-existing conditions and reproductive adverse events, with higher reproductive AEs after vaccination in those without COVID-19 infection than after illness in unvaccina…
DOI: 10.1210/jendso/bvae163.1072 -
Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review
This narrative review comprehensively summarizes cardiovascular and pulmonary adverse effects associated with COVID-19 vaccination, compares these risks to natural SARS-CoV-2 infection, describes clinical presentations and proposed mechanisms, and concludes that vaccination bene…
DOI: 10.3390/vaccines13060548 -
Anti-Spike and Neutralizing Antibodies after Two Doses of COVID-19 Sinopharm/BIBP Vaccine
A cross-sectional study in Egyptian adults (HCWs) vaccinated with two doses of Sinopharm BBIBP-CorV assessing SARS-CoV-2 spike (anti-S) IgG and neutralizing antibodies (nAbs), finding high anti-S seropositivity but lower nAb positivity, with anti-S titers predicting nAb positivi…
DOI: 10.3390/vaccines10081340